The cGAS‐STING pathway plays a vital role in antitumor immunity and, thus, may be a promising pharmacological target for immunotherapy.[7, 8, 9] Several STING agonists have been investigated in clinical trials; however, their results have been unsatisfactory.[10, 11, 12] Mounting evidence suggests that the cGAS‐STING pathway promotes tumor metastasis and induces an immunosuppressive tumor microenvironment (TME).[13, 14, 15] Although the cGAS‐STING pathway has a dual function in tumors, its role in PTCL remains unclear. The gene discussed is STING1; the disease is neoplasm.